Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study

Can we Consider Zoledronic Acid a New Antitumor Agent? Recent Evidence in Clinical Setting

(2010) D. Santini et al.   CURRENT CANCER DRUG TARGETS

Therapeutic Options in the Management of Myeloma Bone Disease

(2010) James R. Berenson   SEMINARS IN ONCOLOGY

Potential Anticancer Properties of Bisphosphonates

(2010) Helen L. Neville-Webbe et al.   SEMINARS IN ONCOLOGY

The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network

(2009) E. Terpos et al.   ANNALS OF ONCOLOGY

Bisphosphonate-associated osteonecrosis of the jaw: what do we currently know? A survey of knowledge given in the recent literature

(2009) Jan Rustemeyer et al.   Clinical Oral Investigations

Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma

(2009) Michele Moschetta et al.   EUROPEAN JOURNAL OF CANCER

A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma

(2008) Pellegrino Musto et al.   CANCER

Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts

(2008) Francesca Patriarca et al.   EUROPEAN JOURNAL OF HAEMATOLOGY